Your LDL is 120 mg/dL. Your ApoB is within range. Your HDL is on the lower end but acceptable. And your Lp(a) is 150 nmol/L — which means your cardiovascular risk is significantly higher than your standard lipid panel suggests. The catch? You have probably never tested Lp(a), and neither has your doctor.
What Is Lp(a)?
Lipoprotein(a) — pronounced "L-p-little-a" — is an LDL-like particle with one critical difference: it carries an additional protein called apolipoprotein(a) attached to its ApoB component. This apolipoprotein(a) is structurally similar to plasminogen, a key clotting protein, which gives Lp(a) its dual danger. It is both pro-atherogenic (like LDL, it deposits cholesterol in artery walls) and pro-thrombotic (it interferes with the body's natural clot-dissolving mechanisms).
The most important fact about Lp(a) is that it is approximately 90% genetically determined. Your Lp(a) level is set by your genes and remains stable throughout your life — it does not change meaningfully with diet, exercise, or most medications. This means a single measurement at any point in your life establishes your risk level permanently. There is no need for annual retesting.
Prevalence is significant: roughly one in five people has an Lp(a) level above 75 nmol/L, the threshold where cardiovascular risk starts to increase meaningfully. Among individuals with a family history of premature cardiovascular disease, the prevalence is even higher — approximately 30% have elevated Lp(a). Despite this, Lp(a) is not included in standard lipid panels and requires a specific order.
Lipoprotein(a) — Lp(a)
Lp(a) and AAS: A Compounding Risk
For AAS users, Lp(a) matters more than it does for the general population. The reason is compounding. AAS suppress HDL cholesterol and raise LDL and ApoB — the classic AAS-induced dyslipidemia pattern. If you have an elevated Lp(a) on top of this, your cardiovascular risk is not simply "LDL risk plus Lp(a) risk." The two factors interact. Lp(a) particles are themselves atherogenic, and their ApoB content adds to the total ApoB burden that drives plaque formation.
Additionally, some evidence suggests that AAS may mildly elevate Lp(a) in certain users, though the effect is inconsistent across studies and compounds. Oral 17-alpha-alkylated compounds appear to have a stronger effect than injectables. If you are using oral AAS and have a family history of early heart disease, testing Lp(a) before and during your cycle provides useful information about whether your specific protocol is influencing this marker.
The practical implication: if your Lp(a) is elevated, your cardiovascular risk management strategy should be more aggressive than it would be for someone with the same LDL and HDL but normal Lp(a). This means tighter control of modifiable risk factors — blood pressure, LDL/ApoB, smoking, glucose — to offset the fixed risk from Lp(a). It also means more careful compound selection, favoring compounds with milder lipid impact.
Who Should Test Lp(a)
Testing and Interpretation
Lp(a) is measured in either nmol/L (particle number) or mg/dL (mass). nmol/L is preferred because Lp(a) particles vary in size, and mass measurements can underestimate risk in individuals with large Lp(a) isoforms. The European Atherosclerosis Society recommends using nmol/L when possible.
- < 30 nmol/L — Optimal. No increased risk from Lp(a).
- 30-75 nmol/L — Borderline. Consider rechecking once in 5-10 years to confirm stability.
- 75-125 nmol/L — Elevated. Moderate risk increase. Manage other risk factors aggressively.
- > 125 nmol/L — High. Significant risk increase. Consider pharmacology options (PCSK9 inhibitors).
For AAS users, the threshold for concern is lower. If your Lp(a) is above 75 nmol/L and you regularly use compounds that suppress HDL and raise ApoB, your cumulative risk profile may warrant aggressive management even at levels that would be considered "borderline" in the general population.
Management Options for Elevated Lp(a)
Lp(a) is notoriously difficult to lower. Lifestyle interventions — diet, exercise, weight loss — have no meaningful effect. Statins, surprisingly, do not lower Lp(a) and may even raise it slightly in some individuals. The options that do work fall into two categories: modest reductions and potent reductions.
Niacin (1-2 g/day) lowers Lp(a) by 15-30%, but its use is limited by side effects: flushing (which can be managed with aspirin taken 30 minutes before dosing), glucose elevation, and gastrointestinal discomfort. Niacin also lowers LDL and raises HDL, making it a multi-purpose option for AAS users with combined dyslipidemia and elevated Lp(a). The extended-release formulation has a better side effect profile than immediate-release.
PCSK9 inhibitors (alirocumab, evolocumab) lower Lp(a) by 25-30% while simultaneously lowering LDL by 50-60%. They are the most effective currently available option for Lp(a) reduction, but they are expensive (approximately $5,000-7,000 per year) and require injection every 2-4 weeks. In most healthcare systems, approval requires a documented history of cardiovascular disease or familial hypercholesterolemia.